Similar articles for PMID: 25085446

Year	Number of Results
2000	2
2001	2
2002	1
2003	1
2004	1
2005	2
2006	1
2007	9
2008	7
2009	10
2010	19
2011	6
2012	19
2013	10
2014	10
2015	4
2016	2
2017	3
2018	1
2024	0

1

No change of the lipid profile under the control of ApoE gene polymorphism in schizophrenics under paliperidone treatment.

Kao WT, Chang CL, Chen YL, Lung FW. Kao WT, et al. Psychiatr Q. 2014 Dec;85(4):487-96. doi: 10.1007/s11126-014-9309-3. Psychiatr Q. 2014. PMID: 25085446

2

Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.

Zhang Y, Dai G. Zhang Y, et al. Hum Psychopharmacol. 2012 Nov;27(6):605-14. doi: 10.1002/hup.2270. Hum Psychopharmacol. 2012. PMID: 24446539 Clinical Trial.

3

Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.

Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, Theodoropoulou P, Fernández LG, Uçok A, Tessier C, Bergmans P, Hoeben D. Schreiner A, et al. J Clin Psychopharmacol. 2012 Aug;32(4):449-57. doi: 10.1097/JCP.0b013e31825cccad. J Clin Psychopharmacol. 2012. PMID: 22722501 Clinical Trial.

4

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.

Hu S, Yao M, Peterson BS, Xu D, Hu J, Tang J, Fan B, Liao Z, Yuan T, Li Y, Yue W, Wei N, Zhou W, Huang M, Xu Y. Hu S, et al. Psychopharmacology (Berl). 2013 Nov;230(1):3-13. doi: 10.1007/s00213-013-3073-1. Epub 2013 Apr 5. Psychopharmacology (Berl). 2013. PMID: 23559220 Clinical Trial.

5

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. De Hert M, et al. CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. CNS Drugs. 2012. PMID: 22900950 Review.

6

Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).

Schreiner A, Hargarter L, Hitschfield K, Lee JI, Lenskaya I, Sulaiman AH, Diels J; PILAR study group. Schreiner A, et al. Curr Med Res Opin. 2014 Jul;30(7):1279-89. doi: 10.1185/03007995.2014.898630. Epub 2014 Mar 19. Curr Med Res Opin. 2014. PMID: 24597755

7

Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.

Chung TS, Lung FW. Chung TS, et al. J Clin Psychopharmacol. 2012 Jun;32(3):394-7. doi: 10.1097/JCP.0b013e31825370f4. J Clin Psychopharmacol. 2012. PMID: 22544010 Clinical Trial.

8

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM. Turkoz I, et al. BMC Psychiatry. 2011 Feb 7;11:21. doi: 10.1186/1471-244X-11-21. BMC Psychiatry. 2011. PMID: 21299844 Free PMC article.

9

Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.

Owen RT. Owen RT. Drugs Today (Barc). 2007 Apr;43(4):249-58. doi: 10.1358/dot.2007.43.4.1067342. Drugs Today (Barc). 2007. PMID: 17460786 Review.

10

Social interaction and drug attitude effectiveness in patients with schizophrenia.

Tsai JK, Lin WK, Lung FW. Tsai JK, et al. Psychiatr Q. 2011 Dec;82(4):343-51. doi: 10.1007/s11126-011-9177-z. Psychiatr Q. 2011. PMID: 21499787 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

99 results

Results by year